Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.47 |
| ▸ | CCR5 | P51681 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ARG1 | P05089 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6011565 | 0.89 | CCR2 (0.49) | CCR5 | |
| SCHEMBL6011653 | 0.87 | SLC6A4 (0.62) | SLC6A3SLC6A4SLC6A2CCR5 | |
| SCHEMBL6011652 | 0.87 | SLC6A4 (0.62) | SLC6A3SLC6A4SLC6A2CCR5 | |
| SCHEMBL27614132 | 0.81 | SLC6A3 (0.45) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6011408 | 0.81 | CCR5 (0.53) | CCR5CYP2D6 | |
| SCHEMBL6011337 | 0.81 | CCR5 (0.53) | SLC6A3SLC6A4SLC6A2CCR5 | |
| SCHEMBL6475214 | 0.77 | CCR5 (0.47) | CCR5 | |
| SCHEMBL6011545 | 0.77 | CCR2 (0.49) | CCR5 | |
| SCHEMBL6011546 | 0.77 | CCR2 (0.49) | CCR5 | |
| SCHEMBL6011420 | 0.77 | SLC6A4 (0.54) | SLC6A3SLC6A4SLC6A2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
| EP-1572650-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056773-A1 | NOVEL PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR CCR5 | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | CCR5, CCR2, CCR1 | SLC6A3 1787/4885SLC6A4 2570/4885SLC6A2 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.